Magnetic resonance imaging method

• US 20020043267A1
• Filed: 08/02/2001
• Published: 04/18/2002
• Est. Priority Date: 04/10/1998
• Status: Active Grant

• Current Assignee: Polarean, Inc. (Polarean Imaging Plc)
• Original Assignee: Medi-Physics Incorporated (General Electric Company)
• Inventors: Roberts, Timothy P.L., Lauer, Lars, Ebert, Michael, Surkau, Reinhard, Deninger, Anselm, Schreiber, Wolfgang, Heil, Werner, Grossmann, Tino, Weiler, Norbert, Eberle, Balthasar, Kauczor, Hans-Ulrich, Markstaller, Klaus
• Granted Patent: US 6,595,211 B2
• Time in Patent Office: Days
• US Class Current: 128/898
• CPC Class Codes: G01R 33/5601 involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Abstract

The invention provides a method of detecting regional variations in oxygen uptake from the lungs of an air-breathing animal subject, said method comprising administering into the lungs of said subject a diagnostically effective amount of a gaseous hyperpolarized magnetic resonance imaging agent, detecting the magnetic resonance signal from said agent in said lungs, determining the temporal variation in relaxation rate for said signal for at least one region of interest within said lungs, and from said variation generating a qualitative or quantitative value or image indicative of the oxygen uptake from the alveolar space in said at least one region of interest.

Claims

1. A method of detecting regional variations in oxygen uptake from the lungs of an air-breathing animal subject, said method comprising administering into the lungs of said subject a diagnostically effective amount of a gaseous hyperpolarized magnetic resonance imaging agent, detecting the magnetic resonance signal from said agent in said lungs, determining the temporal variation in relaxation rate for said signal for at least one region of interest within said lungs, and from said variation generating a qualitative or quantitative value or image indicative of the oxygen concentration in the alveolar space in said at least one region of interest, and if desired the time dependency of such concentration.

2. A method as claimed in claim 1 wherein said hyperpolarized agent comprises ³He.

3. A method as claimed in claim 1 wherein detection of said magnetic resonance signal is effected during a period of at least 1 second during which there is substantially no gas flow into or out of the lungs.

4. A method as claimed in claim 1 wherein said regions of interest comprise regions of alveolar space.

5. A method as claimed in claim 1 wherein a temporal and/or spatial mr image of at least part of the lungs comprising said regions of interest is also generated.

6. A method as claimed in claim 5 wherein said temporal and/or spatial image is constructed from magnetic resonance signals from said hyperpolarized agent.

7. A method as claimed in claim 5 wherein said temporal and/or spatial image is constructed from magnetic resonance signals from magnetic resonance active nuclei in a further magnetic resonance imaging agent administered into the vasculature or lungs of said subject.

8. A method as claimed in claim 7 wherein said further agent comprises a ¹⁹F fluorocarbon.

9. A method as claimed in claim 1 wherein said magnetic resonance signals are detected in at least two different types of magnetic resonance imaging sequence.

10. A method as claimed in claim 9 wherein said types of sequence differ in the intensity of the magnetic resonance signal stimulating radiation.

11. A method as claimed in claim 9 wherein said types of sequence differ in the sequence timing.

12. A method as claimed in claim 9 wherein said types of sequence are interleaved.

13. A method as claimed in claim 1 wherein magnetic resonance signal detection is effected in an imaging sequence with an image acquisition time of less than 2 seconds.

14. A method as claimed in claim 1 wherein magnetic resonance signal detection is effected in an imaging sequence involving imposition of a flip angle of less than 70.

15. A method as claimed in claim 1 wherein said hyperpolarized agent is administered as a bolus.

16. A method as claimed in claim 1 wherein said hyperpolarized agent is administered as a bolus of volume 1 to 1000 ml.

17. A method as claimed in claim 1 wherein a mr imager with a primary field strength in the range of 0.05 to 3.5T is used to defeat said magnetic resonance signal.

18. A method as claimed in claim 1 wherein said hyperpolarized agent comprises ¹²⁹Xe.